Myriad Genetics Inc. (MYGN)
-NasdaqGS | Prev Close: | 25.31 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 34.60 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 22.61 - 38.27 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,853,210 |
|---|
| Market Cap: | 2.04B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 4 Healthcare Stock Stories Making a Big Buzz Todayat Wall St. Cheat Sheet(Tue, Oct 1)
- InPlay: Myriad Genetics and BioMarin (BMRN) advance PARP collaboration into Phase 3Briefing.com(Tue, Oct 1)
- Myriad Genetics, BioMarin advance PARP collaboration into Phase 3theflyonthewall.com(Tue, Oct 1)
- Myriad Genetics and BioMarin Advance PARP Collaboration Into Phase 3GlobeNewswire(Tue, Oct 1)
- Myriad Genetics recovers after Medicare rate woesAP(Tue, Oct 1)
- Analysts: Time Warner Cable Residential Revenues May Rise and 3 Other Research Notes to Look Overat Wall St. Cheat Sheet(Tue, Oct 1)
- Why Myriad Genetics Shares Jumpedat Motley Fool(Tue, Oct 1)
- On The Fly: Midday Wrapat theflyonthewall.com(Tue, Oct 1)
- Myriad rebounds after calling reimbursement cuts an errorat theflyonthewall.com(Tue, Oct 1)
- 3 Stocks Near 52-Week Lows Worth Buyingat Motley Fool(Tue, Oct 1)
- Myriad says CPT code pricing error should correct in 'week or two'theflyonthewall.com(Tue, Oct 1)
- MYRIAD GENETICS INC Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Tue, Oct 1)
- Myriad Genetics upgraded by Ladenburg ThalmannBriefing.com(Tue, Oct 1)
- Trade-Ideas: Myriad Genetics (MYGN) Is Today's "Water-Logged And Getting Wetter" Stockat TheStreet(Mon, Sep 30)
- CMS posts revised gapfill prices for Molecular Pathology CPT codestheflyonthewall.com(Mon, Sep 30)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| MYGN | 0.00% | 2.04B |
| QGEN | 0.00% | 5.16B |
| ACTG | 0.00% | 1.14B |
| FORR | 0.00% | 744.24M |
Key Statistics
| Forward P/E (1 yr): | 11.88 |
|---|
| P/S (ttm): | 3.32 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-14)
: | 1.91 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.46 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 0.78 |
|---|
Business Summary
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States.
View More